Mental health support needs to be included in weight-management care
Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at least comparable benefit to dulaglutide, an older GLP-1 receptor agonist with established cardiovascular efficacy
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y (2022) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Check for air bubbles after drawing
Many patients searching for peptides for weight loss prefer this approach for its regenerative and metabolic benefits
oral semaglutide demonstrated cardiovascular safety (non-inferiority) in the PIONEER 6 trial, but the addition of a stimulant medication may compromise this profile